Ammonium, hexamethylenebis(dimethylethyl-, dibromide | 3614-32-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Ammonium, hexamethylenebis(dimethylethyl-, dibromide
• 英文别名: ethyl-[6-[ethyl(dimethyl)azaniumyl]hexyl]-dimethylazanium;dibromide
• CAS: 3614-32-2
• 化学式: C14H34Br2N2
• 分子量: 390.24
• InChiKey: GGYVFJXFWSWCEZ-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -3.25
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• GANGLIONIC BLOCKING AGENTS FOR THE TREATMENT OF EPITHELIAL DISEASES
  申请人：Dow Pharmaceutical Sciences

  公开号：EP1868594A1

  公开（公告）日：2007-12-26
• Ganglionic blocking agents for the treatment of epithelial diseases
  申请人：Dow J. Gordon

  公开号：US20060216350A1

  公开（公告）日：2006-09-28

  Compositions, and methods of making and using a composition, containing a ganglionic blocking agent and water provide increased penetration of the ganglionic blocking agent into and through epithelial surfaces, such as skin and mucosal surfaces, provide increased release from formulations containing such ganglionic blocking agents, and provide increased antiviral effectiveness compared with compositions containing a ganglionic blocking agents and lacking water.
• [EN] GANGLIONIC BLOCKING AGENTS FOR THE TREATMENT OF EPITHELIAL DISEASES<br/>[FR] GANGLIOPLEGIQUES POUR TRAITER DES MALADIES EPITHELIALES
  申请人：DOW PHARMACEUTICAL SCIENCES

  公开号：WO2006104676A1

  公开（公告）日：2006-10-05

  [EN] Compositions, and methods of making and using a composition, containing a ganglionic blocking agent and water provide increased penetration of the ganglionic blocking agent into and through epithelial surfaces, such as skin and mucosal surfaces, provide increased release from formulations containing such ganglionic blocking agents, and provide increased antiviral effectiveness compared with compositions containing a ganglionic blocking agents and lacking water.
  [FR] L'invention concerne des compositions et des procédés pour réaliser et utiliser une composition contenant un ganglioplégique et de l'eau. Ces compositions présentent une meilleure pénétration du ganglioplégique dans et à travers les surfaces épithéliales telles que la peau et les muqueuses, une libération accrue de formulations contenant des ganglioplégiques de ce type, et un effet antiviral accru comparativement à d'autres compositions contenant un ganglioplégique et de l'eau.